上海恩乐迈生物科技

Enlemai is a clinical-stage biotechnology company headquartered in Shanghai, China, dedicated to developing breakthrough therapies for metabolic disorders. The company focuses on the discovery and development of next-generation peptide drugs, particularly multi-receptor agonists targeting GLP-1, GIP, and Glucagon. Its lead candidate, ELM-101, is a long-acting GLP-1/GIP dual agonist currently undergoing clinical evaluation for obesity and type 2 diabetes. Enlemai aims to address the significant unmet medical needs in the metabolic space by optimizing the efficacy and safety profiles of its candidates through proprietary peptide engineering. The company is backed by prominent venture capital firms and led by a team with extensive experience in metabolic drug R&D.